Actively Recruiting
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
Led by AstraZeneca · Updated on 2025-11-18
150
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.
CONDITIONS
Official Title
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older at the start date
- Diagnosed with unresectable and locally advanced or metastatic PRCC, or with unresectable and locally advanced or metastatic RCC with papillary histology (papillary ≥ 50%) as dominant type
- Received first-line therapy with sunitinib or sorafenib
- Had tumor assessment or relevant clinical visit within 6 months after starting treatment; death events within 6 months are included
You will not qualify if you...
- Diagnosis of papillary urothelial carcinoma or renal pelvis cancer
- History of another primary malignancy except those treated with curative intent and no active disease for 5 years or more
- Received systemic anticancer therapy for PRCC before starting first-line therapy, except neoadjuvant or adjuvant therapy completed more than 12 months before metastatic or recurrent disease diagnosis
- Missing both day and month of treatment start date
- Severe conditions graded 3 or higher by CTCAE 5.0 criteria at study entry
- Treated with any combination of chemotherapy, targeted therapy, or immunotherapy with sunitinib or sorafenib as first-line therapy
- Other exclusion criteria from study D5086C00001 (SAMETA) if explicitly identified in medical records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here